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Phagocytic NADPH Oxidase-Dependent Superoxide
Production Stimulates Matrix Metalloproteinase-9
Implications for Human Atherosclerosis
Guillermo Zalba, Ana Fortun˜o, Josune Orbe, Gorka San Jose´, Marı´a U. Moreno, Miriam Belzunce,
Jose´ Antonio Rodrı´guez, Oscar Beloqui, Jose´ Antonio Pa´ramo, Javier Dı´ez
Objective—Data suggest that matrix metalloproteinase-9 (MMP-9) has a role in atherosclerosis. The phagocytic NADPH
oxidase has been also associated with atherosclerosis. This study aimed to investigate the association between
phagocytic NADPH oxidase and MMP-9 in human atherosclerosis.
Methods and Results—In vitro experiments performed in human monocytes showed that NADPH oxidase activation
enhanced MMP-9 secretion and activity, determined by enzyme-linked immunosorbent assay and zymography,
respectively. Immunohistochemical study showed that phagocytic NADPH oxidase localized with MMP-9 in
endarterectomies from patients with carotid stenosis. In addition, a positive relationship (P0.001) was found between
phagocytic NADPH oxidase-dependent superoxide production determined with lucigenin and plasma MMP-9 levels in
188 asymptomatic subjects free of overt clinical atherosclerosis. In multivariate analysis, this association remained
significant after adjustment for cardiovascular risk factors. Interestingly, subjects in the upper quartile of superoxide
production exhibited the highest values of MMP-9, oxidized low-density lipoprotein, nitrotyrosine, carotid intima media
thickness, and an increased presence of carotid plaques.
Conclusions—Enhanced NADPH oxidase-dependent O2 production stimulates MMP-9 in monocytes and this relation-
ship may be relevant in the atherosclerotic process. Moreover, MMP-9 emerges as an important mediator of the
phagocytic NADPH oxidase-dependent oxidative stress in atherosclerosis. (Arterioscler Thromb Vasc Biol. 2007;27:
587-593.)
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The NADPH oxidase systems, which constitute the mostimportant sources of superoxide (O2) in the vessel wall,
are present in endothelial cells, smooth muscle cells (SMCs),
fibroblasts, and infiltrated monocytes/macrophages.1,2 The
phagocytic NADPH oxidase consists of a membrane-
associated cytochrome b558, which comprises gp91phox and
p22phox subunits, and cytosolic components p47phox, p67phox,
and rac.2
Several studies have shown a key role for vascular
NADPH oxidase isoforms in the development of human
atherosclerosis.3–7 Interestingly, phagocytic NADPH oxidase
seems to play also a key role in the development and
progression of atherosclerotic lesion.5–7 Recently, enhanced
phagocytic NADPH oxidase-dependent O2 production has
been correlated positively with carotid intima-media thick-
ness (IMT), a surrogate marker of atherosclerosis.8
Metalloproteinases (MMPs) are a family of zinc-dependent
endopeptidases capable as a class of degrading extracellular
matrix components, which participate in the atherosclerotic
process by remodeling the extracellular matrix.9 Available
evidence substantiates that plasma MMP-9 levels correlate
with the presence of atherosclerosis10 and represent an inde-
pendent risk factor for atherothrombotic events (ie, coronary
heart disease events and cerebrovascular disease).11,12 Thus,
plasma MMP-9 levels can provide a useful emerging plasma
biomarker in the prediction of atherothrombotic events.13
Whereas NADPH oxidase-mediated O2 generation partici-
pates in MMP-2 and MMP-9 activation in cardiomyocytes,
endothelial cells, and SMCs,14–18 no data are available on its
ability to regulate MMPs in blood phagocytic cells. We
therefore hypothesized that an association may exist between
phagocytic NADPH oxidase and MMP-9 in human athero-
sclerosis. To test this hypothesis, we performed the study at 3
levels; (1) we analyzed in vitro the ability of NADPH oxidase
to regulate MMP-9 in human monocytes; (2) we studied the
association between NADPH oxidase and MMP-9 in athero-
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sclerotic plaques from endarterectomy specimens; and (3) we
explored the relationship of NADPH oxidase with plasma
MMP-9 and carotid atherosclerosis in asymptomatic subjects.
Patients and Methods
Cell Culture Experiments
Human monocytes were isolated from peripheral blood mononuclear
cells with the MACS Column Technology (Miltenyi Biotec) and
maintained in RPMI 1640 supplemented with 0.2% fetal calf serum.
Human THP-1 macrophagic cell line was obtained from ATCC, and
was maintained in RPMI 1640 supplemented with 10% fetal calf
serum. For experiments, cells (500000 cells/mL) were maintained in
RPMI 1640 supplemented with 0.2% fetal calf serum for 24 hours.
After this period of time, cells were incubated with phorbol myristate
acetate (PMA, 6.4108 mol/L) in the presence and the absence of
apocynin, a specific intracellular inhibitor of NADPH oxidase
assembly.
Detection In Vitro of O2 Generation
We measured O2 production in human monocytes in the presence
of 5 mol/L lucigenin. Luminescence was measured for 30 minutes
in a plaque luminometer. A buffer blank was subtracted from each
reading. Data were expressed as relative light units produced per
second. In some experiments, the effects of apocynin, a NADPH
oxidase inhibitor, was studied.
Determination In Vitro of MMP-9 Expression
and Activity
A sandwich enzyme-linked immunosorbent assay (ELISA) (Amer-
sham Biosciences), an assay that quantified both the precursor form
and the active form complexed with the tissue inhibitor of
metalloproteinase-1, was used to determine MMP-9 levels in cul-
tured cell supernatants. MMP-9 gelatinolytic activity was assessed
by zymography in supernatants from cells. Samples were prepared in
nonreducing sample buffer (0.625 mmol/L Tris-HCl, 10% glycerol,
2% SDS, 2% bromphenol blue), and run through 10% zymogram
gelatin gels.
Subjects
Two studies were performed. The first study was performed in 5
male patients (mean age, 67 years) undergoing carotid endarterecto-
my. Surgical intervention criteria were internal carotid stenosis
75%. The second study was performed in 188 consecutive appar-
ently healthy subjects (80% men; mean age, 53 years). The criteria
for defining the absence of atherosclerosis have been recently
described (please see http://atvb.ahajournals.org).8
The studies were performed in subjects referred to our institution
for global cardiovascular risk assessment. The presence of cardio-
vascular risk factors such as diabetes mellitus, arterial hypertension,
dyslipidemia, obesity, metabolic syndrome, and smoking habits was
assessed (please see http://atvb.ahajournals.org). Written informed
consent was obtained from all subjects, the study was performed in
accordance with the Declaration of Helsinki, and the local committee
on human research approved of the study protocol.
Histochemistry
After endarterectomy, tissues were embedded in OCT in liquid N2
and stored at 80°C. Serial sections of 7 m were analyzed by
immunohistochemistry. The primary antibodies were polyclonal
antibodies anti MMP-9 (2 g/mL, Neomarkers) and anti p22phox,
gp91phox, p47phox, and p67phox (0.4 g/mL; Santa Cruz Biotechnol-
ogy). Monoclonal anti CD-68 and anti -actin (0.2 g/mL; Dako)
were used for detection of macrophages and SMCs, respectively.
Sirius red staining was used to identify interstitial collagen on 3-m
sections as described.19
Detection In Situ of O2 Generation
O2 in atherectomies was detected by fluorescence with dihydro-
ethidium (DHE). Unfixed frozen samples were cut into 10-m-thick
sections and placed on glass slides. DHE (10 mol/L) was applied
and incubated in a light-protected humidified chamber at 37°C for 30
minutes. The DHE image was obtained by a laser scanning confocal
imaging system (Zeiss LSM-510 Meta) with a 585-nm long-pass
filter. The specificity of DHE for O2 was demonstrated by
preincubating samples with CuZn-superoxide dismutase (SOD,
10 000 U/mL).
Determination In Vivo of MMP-9
A sandwich ELISA (Amersham Biosciences) was used to determine
MMP-9 levels in plasma samples.
Determination In Vivo of O2 Production
We measured O2 production in peripheral mononuclear cells
isolated from blood samples, in response to stimulation with PMA
(3.2106 mol/L), and using 5 mol/L lucigenin as previously
described (please see http://atvb.ahajournals.org).8
Determination of Circulating Markers of
Oxidative Stress
ELISA was performed to determine plasma levels of protein-
associated 3-nitrotyrosine (NT) (Hycult biotechnology) and oxidized
low-density lipoprotein (Mercodia AB).
Measurement of Carotid IMT and Assessment of
Carotid Plaques
Ultrasonography of the common carotid arteries was performed with
a linear-array transducer (ATL 500 HDI) as previously reported.8
Measurement of IMT was made 1 cm proximal to the carotid bulb of
each common carotid artery at plaque-free sites. Atheroma plaques
were defined as echogenic structures encroaching on the vessel’s
lumen with a distinct area 50% greater than the intimal plus media
thickness of neighboring sites.
Statistical Analysis
Data are expressed as meanSEM. The 2 analysis was used to
search for differences for qualitative variables. Pearson correlation
test was used to assess correlations between O2 production and all
continuous variables. Multivariate linear regression analysis was
performed to evaluate factors related to MMP-9 levels and the
possibility of interactions. For association studies, subjects were
stratified according to quartiles of O2 production (quartile 1, O2
production 8 counts/second; quartile 2, O2 production 8 and
16 counts/second; quartile 3, O2 production 16 and 30
counts/second; quartile 4, O2 production 30 counts/second). The
cardiovascular medication intake (dichotomous: yes versus no) was
tested, but revealed P0.05. Likewise, if each class of cardiovascu-
lar medication were tested separately in the models, they were not
significant covariates at the 5% test level. The linear trend of
variables, according to O2 production quartiles, was compared by
use of ANOVA for continuous variables and the linear test of the 2
analysis for categorical variables.
Results
Study in Cultured Cells
To explore the ability of NADPH oxidase to regulate MMP-9,
the effects of the NADPH oxidase-dependent O2 production
on the activity and secretion of MMP-9 were examined in
fresh human monocytes isolated from five patients. First,
incubation of monocytes with PMA immediately provoked a
threefold enhanced O2 generation (P0.01) (Figure 1A).
This effect was prevented in the presence of apocynin, in a
dose-dependent way, thus supporting the notion that the
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NADPH oxidase has a key role in the PMA-induced O2
generation. Second, incubation of human monocytes with
PMA for 24 hours resulted in a 4-fold increase in secretion of
MMP-9 protein (P0.01) (Figure 1B). This enhanced
MMP-9 secretion was associated with increased gelatinase
MMP-9 activity (Figure 1C). These effects were also pre-
vented in the presence of apocynin. These results were
confirmed by similar experiments performed in THP-1 cells
(supplemental Figure I, available online at
http//atvb.ahajournals.org).
Study in Atherosclerotic Plaques
As shown in Figure 2 (also see supplemental Figure II), the
pattern of expression of the phagocytic NADPH oxidase
subunits (p22phox, gp91phox, p47phox, and p67phox) was similar to
MMP-9 staining. It is noteworthy that NADPH oxidase
expression was intense in the macrophage rich area and
colocalized with MMP-9 staining (supplemental Figure III).
O2 production in endarterectomies was detected by using
DHE staining. O2 was evident in all layers, although an
intense area of O2 production was observed throughout the
macrophage-rich area (Figure 2). DHE fluorescence was
abolished by preincubation with CuZn-SOD, demonstrating
the specificity of the assay for O2 (Figure 2). Interestingly,
O2 staining was similar to phagocytic NADPH oxidase
staining.
The fibrous cap of the lesion was intensely stained for
collagen fibers (Figure 2). The collagen staining was practi-
cally absent throughout the macrophage rich area. Besides,
the diminished collagen staining coincided with enhanced
MMP-9 expression.
These data suggest that infiltrated macrophages may favor
the remodeling of atherosclerotic plaque by inducing the
expression of activated MMP-9 through NADPH oxidase-
dependent O2 production.
Study in Asymptomatic Subjects
The clinical characteristics of the asymptomatic subjects are
shown in Table 1. Whereas the cholesterol values were above
the upper normal limit, the values of the remaining parame-
ters tested were normal.
The values of phagocytic O2 production and plasma
MMP-9 in the whole population were 19.11.2 counts/
second and 14.80.6 ng/mL, respectively. There was a
significant positive bivariate correlation between phagocytic
O2 production and plasma levels of MMP-9 (Figure 3),
which remained highly significant after controlling for age
and sex (supplemental Table I). O2 production was also
significantly associated with triglycerides and body mass
index, with the latter also remaining statistically significant
after controlling for age and sex (supplemental Table I).
When we analyzed only those subjects that were not receiv-
ing cardiovascular treatment, O2 production was also asso-
ciated with systolic blood pressure values, which remained
significant after controlling for age and sex (r0.160,
P0.032). However, plasma MMP-9 did not correlate with
other analyzed variables.
In a multivariate analysis, the association between phago-
cytic O2 production and MMP-9 remained statistically
significant after adjusting for some potentially confounding
cardiovascular risk factors (Table 2), with the O2 production
explaining up to 16% of the MMP-9 variance.
The classification of the subjects by quartiles of O2
production showed a linear trend in MMP-9 levels (P0.05)
(Table 3). Furthermore, values of oxidized low-density li-
poprotein and NT, 2 oxidative stress markers that have been
associated with atherosclerosis, were enhanced in subjects in
the fourth quartile compared with subjects in the other
quartiles (P0.05). Likewise, subjects in the fourth quartile
exhibited higher frequency of carotid plaques and increased
carotid IMT compared with subjects in the other quartiles
(P0.05) (Table 3). Interestingly, carotid IMT exhibited a
positive bivariate correlation with O2 production (r0.262,
P0.001) and MMP-9 (r0.181, P0.017), after controlling
for age and sex. Finally, subjects in the fourth quartile
Figure 1. A, O2 production of human monocytes. Monocytes
were left untreated (baseline), or treated with PMA (6.4108
mol/L) alone or in combination with different doses of apocynin
(2.5 to 0.05 mmol/L). After stimulation, O2 production was
measured by luminescence 30 minutes in a plaque luminometer.
MMP-9 (B) expression and gelatinolytic (C) activity of superna-
tants from human monocytes. Monocytes were left untreated
(baseline), or treated with PMA (6.4108 mol/L) alone or in
combination with apocynin (1 or 0.5 mmol/L). After incubation
for 24 hours, media samples were taken and analyzed by ELISA
and gelatin zymography to assess MMP-9 expression and gela-
tinolytic activity,respectively. Experiments were performed by
duplicate in monocytes isolated from 5 patients. *P0.01 com-
pared with baseline conditions.
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exhibited a higher prevalence of metabolic syndrome and
obesity than subjects in the other quartiles (P0.05).
Discussion
The main findings of this study are as follows: (1) enhanced
phagocytic NADPH oxidase-dependent O2 production stim-
ulates MMP-9 in human monocytes; (2) phagocytic NADPH
oxidase is associated with MMP-9 in plaques from athero-
sclerotic patients; and (3) enhanced phagocytic NADPH
oxidase-dependent O2 production is related to both plasma
levels of MMP-9 and carotid atherosclerosis in asymptomatic
subjects. This relationship is independent of confounding
variables, including some conventional cardiovascular risk
factors.
Figure 2. Histological analysis of human carotid endarterectomies. Micrograph (A) showing hematoxylin-eosin staining of atherectomy specimen.
Inset (B) of the hematoxylin-eosin staining. Immunohistochemical staining (C) for SMCs with -actin. Immunohistochemical staining (D) for macro-
phages with CD68. Immunohistochemical staining (E through H) for NADPH oxidase subunits. Immunohistochemical staining (I) for MMP-9. DHE
staining (J) identified O2 production in a higher magnification of the macrophage rich area. Effect (K) of CuZn-superoxide dismutase (CuZn-SOD,
10 000 U/mL) on DHE staining. Collagen staining (L) with Sirius red by polarized light. Analysis was performed in consecutive sections and is repre-
sentative of 5 specimens. High-resolution images for each panel are available online (please see supplemental Figure II).
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In recent years, it has been demonstrated that reactive
oxygen species (ROS) production may participate in MMP-9
activation.9,20,21 In addition, results from several approaches
using apocynin, a specific intracellular inhibitor of NADPH
oxidase assembly, suggest that NADPH oxidase-mediated
O2 generation mediates the MMP-9 activation in different
cell types, including cardiomyocytes,16 endothelial cells,17
and SMCs.18 In this context, our finding showing that
apocynin attenuated both MMP-9 secretion and activation in
human blood monocytes, demonstrates for the first time that
NADPH oxidase-mediated O2 production stimulates
MMP-9 activity in these cells. We cannot discard other
NADPH oxidase-dependent ROS effects on other MMPs in
human monocytes. In fact, NADPH oxidase-dependent O2
production may participate in MMP-2 activation in other cell
types.14–17,22
The phagocytic NADPH oxidase plays a major role in
human atherosclerosis. It has been reported that the severity
of atherosclerotic lesion correlates with p22phox overexpres-
sion in coronary arteries.4 In addition, gp91phox and p22phox
increase considerably along the progression of human athero-
sclerotic plaques, thus suggesting a causal link between the
phagocytic NADPH oxidase and the development of lesions.6
In fact, contribution of gp91phox to lesion progression is
caused almost entirely by infiltrated monocytes.5,6 Finally,
ROS production, mainly generated by infiltrated inflamma-
tory cells, has been associated with p22phox in atherosclerotic
human coronary arteries.7 Likewise, MMP-9 is involved in
several stages of atherosclerosis through remodeling of the
extracellular matrix.9 In cell studies, degradation of the
matrix by MMP-9 at the endothelial layer promotes recruit-
ment of monocyte-derived cells into the subendothelial
space.23 In experimental models, degradation of the matrix
surrounding SMCs promotes SMC migration,24 whereas mac-
rophage expression of active MMP-9 induces acute plaque
disruption in apolipoprotein E/ mice.25 In this context, our
finding showing that O2 generation and NADPH oxidase
components localized with MMP-9 in macrophage-rich areas
in endarterectomy specimens from atherosclerotic patients
confirms that the in vitro relationship between NADPH
oxidase and MMP-9 in human monocytes is also present in
plaques, and allows us to suggest that phagocytic NADPH
oxidase-dependent ROS may promote MMP-9-dependent
degradation of extracellular matrix and the development of
atherosclerotic disease.
Phagocytic NADPH oxidase has been associated with
subclinical atherosclerosis (ie, carotid IMT) in asymptomatic
subjects,8 thus suggesting that NADPH oxidase-mediated
ROS production plays a crucial role in the initiation and
development of atherosclerotic disease. It is thus likely that
MMP-9 might be a potential mediator of the NADPH
oxidase-dependent ROS production in the atherosclerotic
process. In support of this possibility, we found a positive




Body mass index, kg/m2 281
Systolic blood pressure, mm Hg 1311
Diastolic blood pressure, mm Hg 831
Glucose, mmol/L 5.770.11
Total cholesterol, mmol/L 5.840.08
HDL cholesterol, mmol/L 1.220.03










Oral hypoglycemics, % 10†
*Antihypertensives included angiotensin converting enzyme inhibitors (10%),
angiotensin type 1 receptor antagonists (9%) and calcium channels blockers
(12%).
†None of the diabetic patients was treated with insulin.
HDL indicates high-density lipoprotein; LDL, low-density lipoprotein.
Figure 3. Positive correlation between NADPH oxidase-
dependent O2 production and plasma levels of MMP-9
(y10.980.19x, r0.411, P0.001).
TABLE 2. Association of the MMP-9 with NADPH
Oxidase-Dependent O2 Production in Multiple Linear
Regression Analysis
Independent Variables  P* Partial r2 (%)
O2 production, counts/sec 0.386 0.001 16.0
Age, y 0.013 0.866 0.1
Sex, F/M 0.036 0.628 0.1
Body mass index, kg/m2 0.025 0.745 0.1
Systolic blood pressure, mm Hg 0.072 0.365 0.4
Glucose, mmol/L 0.005 0.258 0.5
Smokers, no/yes 0.033 0.659 0.2
Triglycerides, mmol/L 0.001 0.577 0.1
*Adjusted for age, sex, body mass index, systolic blood pressure, glucose,
smoking, and triglycerides; r2 for the total population was 17.4%
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correlation between NADPH oxidase-dependent O2 produc-
tion and MMP-9 levels in asymptomatic subjects. In addition,
findings showing that subjects in the upper quartile of O2
production exhibited increased values of MMP-9, and were
associated with high levels of oxidative stress markers and
with enhanced carotid IMT and frequency of plaques, iden-
tifies a subgroup of subjects who might be prone to develop
plaque rupture and/or ischemic events. In fact, it has been
shown that MMP-9 levels provide a useful emerging biomar-
ker in the prediction of atherothrombotic events.13 Thus,
epidemiologic studies suggest that MMP-9 expression corre-
lates with lesion stability and clinical manifestations of
atherosclerosis.16,26 –28 In addition, analysis of coronary
atherectomies reveal active synthesis of MMP-9 by macro-
phages in lesions of patients with unstable versus stable
angina.29
During the past decade, a significant number of studies
support an essential role of vascular NADPH oxidase iso-
forms (Nox1 and Nox4) in vascular remodeling30–33 and
atherogenesis.11–15 Because the present study does not pro-
vide direct evidence of the potential role of vascular NADPH
oxidases, it is important to point out that the increased
phagocytic NADPH oxidase-dependent O2 production
might not necessarily be the only factor responsible for the
increased MMP-9 levels.8 In fact, our findings showing that
O2 production explained up to 16% of the MMP-9 variance
after adjusting for common risk factors, suggest that vascular
NADPH oxidases may also be participating in the atheroscle-
rotic process.3–7 We should also take into account the fact that
several enzymes have been proposed as sources of ROS in
atherosclerosis other than NADPH oxidases, such as lipoxy-
genase, xanthine oxidase, and nitric oxide synthase.34
Cardiovascular treatment, including antihypertensive
drugs,35,36 statins,37 and tiazolidinediones,38 may reduce
NADPH oxidase activity. In the current study, we found no
association between O2 production and blood pressure
values in the whole population, which included 99 subjects
using cardiovascular medication, contrary to results of a
previous study.39 Nevertheless, our results showed a positive
association between O2 production and systolic blood pres-
sure in subjects who were not receiving cardiovascular
medication, thus demonstrating a critical role of cardiovas-
cular drugs on phagocytic NADPH oxidase activity.
In summary, we found that enhanced NADPH oxidase-
dependent O2 production stimulates MMP-9 in monocytes
and that this relationship may be relevant in the atheroscle-
rotic process. In fact, MMP-9 emerges as a potential mediator
of the pro-atherosclerotic actions of phagocytic NADPH
oxidase in both symptomatic and asymptomatic subjects.
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